Search

313 results for "lecanemab".

Research summaries 284

Showing the best 200 of 284, 31–40, page 4 of 20. Filter these by subject, year and score in the research library →

1. Lecanemab (Leqembi) is not the right drug for patients with Alzheimer's diseaseResearch summary

   Research summaries · alzhub.org/study/lecanemab-leqembi-is-not-the-right-drug-for-patients-with-alzheimer-s-37676096

   … Administration (FDA) approved lecanemab (Leqembi) for the treatment of Alzheimer's dementia (AD) patients. In 2 clinical trials, lecanemab reduced amyloid in the brain and slowed cognitive decline. Here, I review in detail the …

2. Lecanemab for Alzheimer's Disease: Effectiveness and Value — Final Evidence ReportResearch summary

   Research summaries · alzhub.org/study/lecanemab-for-alzheimer-s-disease-effectiveness-and-value-final-40d8b15f

   An independent US drug-pricing watchdog analyzed how lecanemab's actual price compares to its clinical benefit. It concluded the drug would need to cost roughly $8,900 to $21,500 per year to be considered good value for money by …

3. Safety of Lecanemab After 6‐Month Treatment in the DIAN‐TU‐001 TrialResearch summary

   Research summaries · alzhub.org/study/safety-of-lecanemab-after-6month-treatment-in-the-diantu001-trial-41447712

   Lecanemab was generally well-tolerated during the 6-month lecanemab-only treatment period. Overall, 80.4% of the 97 participants enrolled and treated experienced an adverse event. The most common AEs were ARIA-H (26.8%), headache …

4. Clarity AD: Asian regional analysis of a phase III trial of lecanemab in early Alzheimer's diseaseResearch summary

   Research summaries · alzhub.org/study/clarity-ad-asian-regional-analysis-of-a-phase-iii-trial-of-lecanemab-40189473

   … Singapore:13). The efficacy of lecanemab was consistent with the overall population. For the primary endpoint, there was a slowing of decline with lecanemab in the CDR-SB at 18 months compared to placebo in the Asian region …

5. Commentaries: Lecanemab: pioneering the way as the first approved drug for Alzheimer's disease treatmentResearch summary

   Research summaries · alzhub.org/study/commentaries-lecanemab-pioneering-the-way-as-the-first-approved-drug-37682322

   … disease progression. Lecanemab, an anti-amyloid antibody, binds to amyloid-beta (Aβ) protofibrils. Phase II trials revealed dose-dependent amyloid clearance and reduced clinical decline. Phase III trials demonstrated cognitive …

6. Eligibility for lecanemab and donanemab in Korea under Appropriate Use RecommendationsResearch summary

   Research summaries · alzhub.org/study/eligibility-for-lecanemab-and-donanemab-in-korea-under-appropriate-41225766

   … 24.6% were eligible for lecanemab and 28.0% for donanemab (9.1% and 10.3% of the initial sample). Applying MMSE z-scores increased eligibility to 38.4% and 33.7%, respectively. Over a third of participants were excluded due to …

7. Implications of the Approval of Lecanemab for Alzheimer Disease Patient Care: Incremental Step or Paradigm Shift?Research summary

   Research summaries · alzhub.org/study/implications-of-the-approval-of-lecanemab-for-alzheimer-disease-37295957

   … 3 clinical trial of lecanemab have reported clinical benefits linked to amyloid removal. Lecanemab (trade name, Leqembi) is the first with published phase 3 trial results. When administered through IV every 2 weeks to patients …

8. Lecanemab (BAN2401): an anti-beta-amyloid monoclonal antibody for the treatment of Alzheimer diseaseResearch summary

   Research summaries · alzhub.org/study/lecanemab-ban2401-an-anti-beta-amyloid-monoclonal-antibody-for-the-36749830

   … more specific Aβ types. Lecanemab Eisai has a high affinity for large and soluble Aβ protofibrils. This review describes lecanemab, an anti-beta-amyloid monoclonal antibody with high affinity for large soluble Aβ protofibrils, …

9. Lecanemab for early Alzheimer's disease: Appropriate use recommendations from the French federation of memory clinicsResearch summary

   Research summaries · alzhub.org/study/lecanemab-for-early-alzheimer-s-disease-appropriate-use-40011173

   Lecanemab, a monoclonal antibody targeting β-amyloid protofibrils, has shown promising results in a Phase III clinical trial for the treatment of early stages of Alzheimer's disease (AD) and has been approved by the European …

10. Lecanemab in DIAD: 6‐Month Amyloid PET Results from the DIAN‐TU‐001 TrialResearch summary

    Research summaries · alzhub.org/study/lecanemab-in-diad-6month-amyloid-pet-results-from-the-diantu001-trial-41447716

    … anti‐amyloid‐beta antibody lecanemab. Herein, we provide the first results of lecanemab (open‐label) on amyloid PET in a symptomatic DIAD population (the asymptomatic cohort will be evaluated later). Methods The DIAN‐TU‐001 Tau …

How this search works

There is no outside search company involved. The site builds its own index by reading its own pages — the same words you would see on the page — and each result shows a literal snippet of that text with your words highlighted. Nothing is summarised or rewritten by a machine in between.

One addition, made by hand: a short list of everyday words that our pages cover under another name. Search "symptoms" and you are also shown The 10 warning signs; "medication" leads to Treatments & medicines; "hotline" to the helplines. A result reached that way shows the page's own description, and it only ever points to a page that already covers the subject.

27981 pages, questions, glossary terms and research summaries are indexed, last rebuilt 2026-11-04. Las páginas en español también aparecen en estos resultados. The clinical trial records are not in this index — they have their own finder, which searches all trial titles, sponsors and drugs directly.